SCHEDULE: FMR LLC Discloses 8.3% Stake in Cartesian Therapeutics
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting an 8.3% beneficial ownership stake in Cartesian Therapeutics Inc.'s common stock.
Summary
- FMR LLC and Abigail P. Johnson have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in CARTESIAN THERAPEUTICS INC.
- The filing indicates that FMR LLC and Abigail P. Johnson beneficially own 2,155,783 shares of CARTESIAN THERAPEUTICS INC. common stock.
- This aggregate amount represents 8.3% of the total outstanding common stock of CARTESIAN THERAPEUTICS INC.
- FMR LLC holds sole voting power over 2,155,410 shares and sole dispositive power over 2,155,783 shares.
- Abigail P. Johnson, as a Director, Chairman, and CEO of FMR LLC, is deemed to beneficially own the same 2,155,783 shares with sole dispositive power.
- The filing states the event requiring this statement occurred on September 30, 2025.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive. While a Schedule 13G is a factual disclosure, a significant stake by a reputable institutional investor like FMR LLC generally implies a degree of confidence in the company's value or future prospects, which can be viewed favorably by the market.
Positives
- A significant stake by a major institutional investor like FMR LLC can signal confidence in the company's long-term prospects.
- The continued ownership by FMR LLC, as indicated by an amendment, suggests a sustained investment interest in Cartesian Therapeutics Inc.
Negatives
- This filing is a standard disclosure of ownership and does not inherently contain negative information about the company's performance or outlook.
Risks
- This Schedule 13G filing primarily reports beneficial ownership and does not detail specific risks related to Cartesian Therapeutics Inc.'s operations or financial health.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Cartesian Therapeutics Inc.'s future performance or strategic direction.
Industry Context
The filing of a Schedule 13G indicates that a passive institutional investor, FMR LLC, has acquired a significant stake (over 5%) in Cartesian Therapeutics Inc. This is a routine disclosure required by the SEC for large shareholders and provides transparency into major ownership positions within publicly traded companies. Such filings are closely watched by the market as they can signal institutional interest in a company, particularly in the biotechnology or pharmaceutical sector where Cartesian Therapeutics Inc. likely operates.
Comparison to Industry Standards
- The 8.3% stake held by FMR LLC is a substantial position for an institutional investor in a public company, often indicating a long-term, passive investment strategy.
- Compared to other institutional holdings in the biotechnology sector, a stake of this size from a prominent asset manager like FMR LLC (Fidelity) is common and generally viewed as a positive indicator of investor confidence in the company's potential.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by FMR LLC may instill confidence among existing shareholders and potentially attract new investors, positively influencing share price.
- Management: Management may view this as a vote of confidence from a major investor, but it also means increased scrutiny and potential influence from a large shareholder, even if passive.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC and its subsidiaries. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number: -23-000003) was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where Abigail P. Johnson's Power of Attorney (accession number: -23-000038) was incorporated by reference. |
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-11-04 | Signature date of the Schedule 13G Amendment No. 2. |
Recommendation
holdThe filing indicates a significant, passive ownership stake by a major institutional investor, FMR LLC. While this is generally a positive signal of institutional confidence, a Schedule 13G filing itself does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a substantial existing investment. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions while awaiting further operational updates or financial results from Cartesian Therapeutics Inc.
Keywords
CARTESIAN THERAPEUTICS INC, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.